SCHEMBL1336971

SCHEMBL1336971

Cc1ccc([N+](=O)[O-])cc1N(Cc1ccncc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
ALDH1A1 P00352 4/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
TSHR P16473 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
HTT P42858 3/20 0.42
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
TP53 P04637 1/20 0.41
SLC2A1 P11166 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336969 1.00 POLB (0.46) POLBALDH1A1LMNAMAPTMEN1
SCHEMBL11735944 0.82 TP53 (0.52) ALDH1A1LMNAMAPTKMT2AL3MBTL1
SCHEMBL11735933 0.82 TP53 (0.52) ALDH1A1LMNAMAPTKMT2AL3MBTL1
SCHEMBL23320462 0.81 POLB (0.57) POLBALDH1A1LMNAMAPTMEN1
SCHEMBL1336792 0.80 ALDH1A1 (0.62) POLBALDH1A1LMNAMAPTMEN1
SCHEMBL1336794 0.80 ALDH1A1 (0.62) POLBALDH1A1LMNAMAPTMEN1
SCHEMBL18147425 0.79 ALDH1A1 (0.45) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL11765352 0.75 ALDH1A1 (0.53) POLBALDH1A1LMNAMAPTMEN1
SCHEMBL11765362 0.75 ALDH1A1 (0.53) POLBALDH1A1LMNAMAPTMEN1
SCHEMBL1131015 0.73 CRHBP (0.58) POLBALDH1A1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US claimed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP claimed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics GPR119, GLP1R, ADIPOR1 POLB 4125/4885ALDH1A1 2141/4885LMNA 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.